HCmed Innovations CoTPE:6934 -2.16%11 EBIT per Share is NT$-0.86 as of Dec. 2025. GuruFocus rates TPE:6934 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review. Among 690 Medical Devices & Instruments companies, HCmed Innovations Co ranks better than 62.17% on this metric.
HCmed Innovations Co's EBIT per Share for the
three
months ended in Dec. 2025 was NT$0.23.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.86.
During the past 3 years, the average EBIT per Share Growth Rate was 17.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for HCmed Innovations Co's EBIT per Share or its related term are showing as below:
TPE:6934'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 17.9 Med: 18.2 Max: 18.5
Current: 17.9
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of HCmed Innovations Co was 18.50% per year. The lowest was 17.90% per year. And the median was 18.20% per year.
TPE:6934's 3-Year EBIT Growth Rate is ranked better than 62.17% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs TPE:6934: 17.90
HCmed Innovations Co (TPE:6934) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
HCmed Innovations Co EBIT per Share Related Terms
HCmed Innovations Co EBIT per Share Historical Data
* Premium members only.
The historical data trend for HCmed Innovations Co's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.86
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCmed Innovations Co (TPE:6934) has a EBIT per Share of NT$-0.86 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on HCmed Innovations Co and its competitors. According to the industry distribution chart, HCmed Innovations Co ranks #261 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 37.8%.
Is HCmed Innovations Co's EBIT per Share too high?
HCmed Innovations Co's current EBIT per Share is NT$-0.86. Based on the distribution chart, HCmed Innovations Co ranks #261 out of 690 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, HCmed Innovations Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does HCmed Innovations Co's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HCmed Innovations Co ranks #261 out of 690 companies for EBIT per Share. This puts HCmed Innovations Co in the upper half of its industry. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on HCmed Innovations Co and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCmed Innovations Co's current EBIT per Share is NT$-0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCmed Innovations Co stock overvalued right now?
HCmed Innovations Co (TPE:6934) has a current EBIT per Share of NT$-0.86. The current EBIT per Share is NT$-0.86. HCmed Innovations Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For HCmed Innovations Co (TPE:6934), the current EBIT per Share is NT$-0.86 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HCmed Innovations Co Ltd is engaged in designing, developing, manufacturing and selling drug delivery system. It is focused on inhalation therapy to create integrated drug nebulizer combination products featuring nebulization therapeutic drugs that include small molecule synthetics and large molecule biologics, as either solutions, suspensions, and even difficult-to-deliver high viscosity drugs. Its product includes Pulmogine. Geographically, the company operates in America, Europe, Asian and African regions.
11GF Score
Get the complete analysis for TPE:6934
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6934 has been successfully added to your 
